86% of all B2B deals stall — how to spot at-risk deals before the forecast lies

Why do so many B2B deals die quietly?

Around 86% of all B2B buying processes stall at some point, and the most common "winner" is not a competitor but the status quo — the decision to decide nothing ("no decision"). The reason: in economically uncertain times, buyers are more risk-averse than ever. Their biggest fear is not the wrong vendor, but the wrong decision reflecting badly on them. Deals therefore rarely die loudly — they quietly fade while the forecast still lists them as "likely."

What brings a deal to a standstill in 2026

• Growing buying committees: complex deals now involve 6 to 8 decision-makers on average (per RAIN Group) — IT checks security, Legal checks compliance, Finance checks the hard ROI.
• Risk aversion in the C-suite: no one risks their job over a software decision.
• Longer cycles: buying processes stretch from 6 to 9+ months — time in which a deal "falls asleep" unnoticed.

For the head of sales that means: nothing can be forecast reliably to the CEO, because half the pipeline hangs in a limbo no one sees.

Why the CRM does not catch this

A CRM shows you a deal's stage — but not its health. A deal can sit in "negotiation" for weeks and still be dead. The CRM documents the last state; it does not warn you when a deal shows the signs of dying:

• The economic buyer (CFO) was never in a conversation.
• Weeks have passed since the last real progress.
• Communication has become one-sided — sales writes, the customer no longer replies.
• There is no defined next step with a date.

Each of these signals alone looks harmless. Together they are a deal's death sentence — and that is exactly what a filing-cabinet CRM misses.

How a deal health score surfaces at-risk deals early

A deal health score condenses precisely these signals into a single, honest rating per deal. Instead of relying on the rep's gut, you see objectively:

This makes at-risk deals visible while you can still save them — not only when they show up in the quarterly review as "lost to no decision."

From reacting to preventing

The crucial shift: away from the weekly pipeline interrogation ("What's the status on deal X?") toward a system that continuously flags which deals need attention. The head of sales then directs the team's scarce time to the deals that are tipping — before they tip.

Read next: Why your AI forecast is wrong and What is an Autonomous Sales Execution Ecosystem?

Bottom line

When 86% of deals stall, the winner is not whoever has the most deals in the pipeline, but whoever spots earliest which of them are at risk. An objective deal health score turns an invisible black box into an early-warning system — and turns a forecast that hopes into a forecast that knows.